{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T02:39:31Z","timestamp":1788230371283,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.xcrm.2025.102518","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T15:46:28Z","timestamp":1767023188000},"page":"102518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["DF6215, an \u03b1-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5222-3156","authenticated-orcid":false,"given":"Adam P.","family":"Stockmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Herschelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Shin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingya","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart W.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai","family":"Wagtmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann F.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102518_bib1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102518_bib2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","article-title":"Interleukin-2: Biology, Design and Application","volume":"36","author":"Arenas-Ramirez","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.xcrm.2025.102518_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting IL-2: Biology and therapeutic prospects","volume":"3","author":"Abbas","year":"2018","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2025.102518_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev.iy.11.040193.001333","article-title":"The IL-2 receptor complex: its structure, function, and target genes","volume":"11","author":"Minami","year":"1993","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102518_bib5","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1084\/jem.166.4.1055","article-title":"The interleukin 2 receptor. Functional consequences of its bimolecular structure","volume":"166","author":"Wang","year":"1987","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2025.102518_bib6","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191247","article-title":"Effects of interleukin-2 in immunostimulation and immunosuppression","volume":"217","author":"Pol","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2025.102518_bib7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102518_bib8","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3390\/cancers13081850","article-title":"Recruitment and Expansion of Tregs Cells in the Tumor Environment-How to Target Them?","volume":"13","author":"Cinier","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2025.102518_bib9","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s43018-023-00612-0","article-title":"IL-2R\u03b1-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells","volume":"4","author":"Wu","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2025.102518_bib10","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.coi.2011.08.003","article-title":"IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation","volume":"23","author":"Liao","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.xcrm.2025.102518_bib11","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.4049\/jimmunol.175.12.8003","article-title":"IL-2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferation","author":"Janas","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102518_bib12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/291335a0","article-title":"Interleukin-2 augments natural killer cell activity","volume":"291","author":"Henney","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102518_bib13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nm866","article-title":"Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo","volume":"9","author":"Blattman","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102518_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","article-title":"PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program","volume":"610","author":"Hashimoto","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102518_bib15","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1016\/j.immuni.2023.11.005","article-title":"Stat5 opposes the transcription factor Tox and rewires exhausted CD8+ T cells toward durable effector-like states during chronic antigen exposure","volume":"56","author":"Beltra","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2025.102518_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2025.102518_bib17","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nm.2365","article-title":"A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy","volume":"17","author":"Wuest","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102518_bib18","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: The first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102518_bib19","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ccell.2024.02.013","article-title":"Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers","volume":"42","author":"Beck","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102518_bib20","doi-asserted-by":"crossref","first-page":"7440","DOI":"10.1158\/1078-0432.CCR-11-1650","article-title":"Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma","volume":"17","author":"Weiss","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102518_bib21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer","volume":"22","author":"Hernandez","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102518_bib22","first-page":"4202","article-title":"Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial","volume":"47","author":"Thompson","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102518_bib23","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.4049\/jimmunol.135.4.2865","article-title":"In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2","volume":"135","author":"Lotze","year":"1985","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102518_bib24","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","article-title":"Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer","volume":"21","author":"Yang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102518_bib25","first-page":"2009","article-title":"Pharmacokinetics of Recombinant Interleukin 2 in Humans","volume":"50","author":"Konrad","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102518_bib26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2125.1998.00036.x","article-title":"Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application","volume":"46","author":"Kirchner","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102518_bib54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0162-3109(97)00041-6","article-title":"Vascular leak syndrome: a side effect of immunotherapy","volume":"37","author":"Baluna","year":"1997","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.xcrm.2025.102518_bib27","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1002569107","article-title":"Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells","volume":"107","author":"Krieg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102518_bib28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014","volume":"2","author":"Dutcher","year":"2014","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102518_bib29","first-page":"79","article-title":"Update on use of aldesleukin for treatment of high-risk metastatic melanoma","volume":"4","author":"Amaria","year":"2015","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.xcrm.2025.102518_bib30","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","article-title":"NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models","volume":"22","author":"Charych","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102518_bib31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/2159-8290.CD-18-1495","article-title":"A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2R\u03b2\u03b3-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors","volume":"9","author":"Bentebibel","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102518_bib32","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1200\/JCO.21.00675","article-title":"Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma","volume":"39","author":"Diab","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102518_bib33","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1200\/JCO.23.00172","article-title":"Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results","volume":"41","author":"Diab","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102518_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00063030-200822010-00002","article-title":"Fc-Based Cytokines: Prospects for Engineering Superior Therapeutics","volume":"22","author":"Jazayeri","year":"2008","journal-title":"BioDrugs"},{"key":"10.1016\/j.xcrm.2025.102518_bib35","doi-asserted-by":"crossref","first-page":"7183","DOI":"10.1073\/pnas.2000419117","article-title":"Interleukin-2 druggability is modulated by global conformational transitions controlled by a helical capping switch","volume":"117","author":"De Paula","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.xcrm.2025.102518_bib36","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2117401119","article-title":"Interleukin-2 superkines by computational design","volume":"119","author":"Ren","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.xcrm.2025.102518_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00394","article-title":"Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins","volume":"7","author":"Ha","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102518_bib38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13238-017-0473-8","article-title":"IgG Fc engineering to modulate antibody effector functions","volume":"9","author":"Wang","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.xcrm.2025.102518_bib39","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1074\/jbc.M116.767749","article-title":"Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice","volume":"292","author":"Lo","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2025.102518_bib40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1158\/2326-6066.CIR-16-0114","article-title":"Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery","volume":"5","author":"Mosely","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2025.102518_bib41","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2014-07-587493","article-title":"Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy","volume":"124","author":"Van Gool","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102518_bib42","first-page":"37","article-title":"Pathogenesis of toxicity with human-derived interleukin-2 in experimental animals","volume":"34","author":"Harada","year":"1993","journal-title":"Int. Rev. Exp. Pathol."},{"key":"10.1016\/j.xcrm.2025.102518_bib43","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/ni.3076","article-title":"Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses","volume":"16","author":"Shrestha","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2025.102518_bib44","first-page":"2521","article-title":"PTEN inhibits IL-2 receptor-mediated expansion of CD4+CD25+ Tregs","volume":"116","author":"Walsh","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102518_bib45","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","article-title":"NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models","volume":"22","author":"Charych","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102518_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003155","article-title":"Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate","volume":"10","author":"Merchant","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102518_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000673","article-title":"ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy","volume":"8","author":"Lopes","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102518_bib48","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/2326-6066.CIR-21-0831","article-title":"Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression","volume":"10","author":"Nirschl","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2025.102518_bib49","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1158\/1078-0432.CCR-19-3354","article-title":"CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies","volume":"26","author":"Quayle","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102518_bib50","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1158\/1078-0432.CCR-10-2921","article-title":"A Low-Toxicity IL-2\u2013Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity","volume":"17","author":"Gillies","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102518_bib51","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2024.05.540","article-title":"VP4-2024: First-in-class PD-1\/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study","volume":"35","author":"Bai","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102518_bib52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","article-title":"PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells","volume":"610","author":"Codarri Deak","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102518_bib53","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1158\/2159-8290.CD-23-1266","article-title":"IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity","volume":"14","author":"Moynihan","year":"2024","journal-title":"Cancer Discov."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T03:21:30Z","timestamp":1775186490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125005919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2666379125005919"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102518","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DF6215, an \u03b1-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102518","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102518"}}